Collaboration
propels innovation
Who we are
Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc. and Glenmark Pharmaceuticals Limited, combines internal prowess and external potentialities to create cutting-edge therapy solutions.
Solutions that treat hematological malignancies and solid tumors to bring new hope for patients, their families and healthcare professionals alike.
At a Glance
- Innovation at IGI
- Leadership
- Centers of Innovation
Innovation at IGI
- Diversity of immune cell engagement and indications across hematologic and solid tumors
- Proprietary protein engineering platform allowing maximal flexibility and manufacturability of full length multispecific antibodies
- Discovery engine to sustain innovation and drive long-term growth
Leadership
- A highly experienced management team with a combined experience of 144 years
- Approximately 150+ employees singularly focused on pushing the boundaries of oncology cancer treatment/therapy
- Scientific Advisory Board with extensive expertise in drug development, immuno-oncology, and protein engineering
Centers of Innovation
3 state-of-the-art centers of innovation in USA, Switzerland and India
- Company headquarters in New York, USA, focused on clinical development, general and administration
- Biologics and early discovery research center at Biopôle, Lausanne in Switzerland
- Small Molecule Research Center at Mahape in Mumbai, India
Robust pipeline
- ISB 1442 (CD38 x CD47): Phase 1
- ISB 2001 (BCMA x CD38 x CD3): Phase 1
- GRC 54276 - HPK1 inhibitor: Phase 1
ISB 1442 (CD38 x CD47): Phase 1
ISB 2001 (BCMA x CD38 x CD3): Phase 1
GRC 54276 - HPK1 inhibitor: Phase 1
Robust Pipeline
ISB 1442 (CD38 x CD47) :
Phase 1
Phase 1
ISB 2001 (BCMA x CD38 x CD3):
Phase 1
Phase 1
GRC 54276 - HPK1 inhibitor:
Phase 1
Phase 1
Latest Updates
PRESS RELEASE
30 Sept 2024
